Published on: 2025-07-10 16:55:05
Glioblastoma is the deadliest form of brain cancer. Patients diagnosed with glioblastoma have a median survival time of 15 to 18 months, and standard treatments have remained largely unchanged for two decades: surgery, chemotherapy, and radiation. A recent study, however, claims to have discovered a potential new therapy with a unique approach. Researchers in Los Angeles have developed a way to force glioblastoma cells into a harmless, non-dividing state by combining radiation therapy with fors
Keywords: cancer cells forskolin glioblastoma radiation
Find related items on AmazonPublished on: 2025-07-11 08:24:22
Glioblastoma is a highly aggressive and lethal brain cancer with an average survival time of 12 to 18 months. Only 25% of patients survive more than one year and less than 5% survive more than 3 years. The new publication shares the experimental treatment given to a patient diagnosed with glioblastoma. Prof Long used her expertise in immunotherapy and drew on melanoma science to devise, lead and administer the treatment. It is the first documented use of neoadjuvant triple immunotherapy in gl
Keywords: cells glioblastoma immune immunotherapy treatment
Find related items on AmazonGo K’awiil is a project by nerdhub.co that curates technology news from a variety of trusted sources. We built this site because, although news aggregation is incredibly useful, many platforms are cluttered with intrusive ads and heavy JavaScript that can make mobile browsing a hassle. By hand-selecting our favorite tech news outlets, we’ve created a cleaner, more mobile-friendly experience.
Your privacy is important to us. Go K’awiil does not use analytics tools such as Facebook Pixel or Google Analytics. The only tracking occurs through affiliate links to amazon.com, which are tagged with our Amazon affiliate code, helping us earn a small commission.
We are not currently offering ad space. However, if you’re interested in advertising with us, please get in touch at [email protected] and we’ll be happy to review your submission.